Maximum recommended dose of olmesartan
Pro Research Analysisby 
Searched over 200M research papers
Maximum Recommended Dose of Olmesartan for Hypertension
Olmesartan Maximum Dose in Adults
The maximum recommended daily dose of olmesartan for adults is 40 mg per day. This dose is considered effective for the treatment of hypertension and is supported by clinical studies showing its efficacy and safety profile at this level Brousil2003Brunner2004Salazar2012+2 MORE. For patients with severe renal insufficiency (creatinine clearance <20 mL/min) or moderate hepatic insufficiency (Child-Pugh score 7–9), the daily dose should not exceed 20 mg .
Olmesartan in Combination Therapy
When olmesartan is used in combination with hydrochlorothiazide, the maximum recommended dose is 40 mg of olmesartan with 25 mg of hydrochlorothiazide per day. Dose adjustments can be made after 2 to 4 weeks as needed, but should not exceed this combination maximum Brunner2004Salazar2012Oparil2001.
Dose-Response and Efficacy
Clinical studies have shown that olmesartan produces a dose-dependent reduction in blood pressure, with the 20 mg dose often considered optimal for many patients. However, higher doses up to 40 mg provide additional blood pressure lowering and are well tolerated, especially in patients who do not achieve target blood pressure with lower doses or monotherapy Rump2010Oparil2001Заннад2010+1 MORE. Doses above 40 mg have been studied but are not generally recommended for routine clinical use .
Pediatric Dosing
For pediatric patients aged 6 to 16 years, dosing is based on body weight: 10 mg daily for those weighing less than 35 kg, and 20 mg daily for those weighing 35 kg or more . The maximum dose in pediatric patients should not exceed these recommendations.
Conclusion
The maximum recommended dose of olmesartan for adults is 40 mg per day, with lower limits advised for patients with significant renal or hepatic impairment. In combination therapy with hydrochlorothiazide, the maximum is 40 mg/25 mg per day. These dosing recommendations are supported by multiple clinical studies demonstrating both efficacy and safety at these levels.
Sources and full results
Most relevant research papers on this topic
The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects
Olmesartan medoxomil effectively reduces blood pressure in pediatric patients aged 6-16 years, with 10 mg for those weighing 35 kg and 20 mg for those weighing 35 kg.
Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
Olmesartan, at its starting dose, is more effective than other ARBs in reducing cuff diastolic blood pressure in patients with essential hypertension.
АНТИГИПЕРТЕНЗИВНАЯ ЭФФЕКТИВНОСТЬ ОЛМЕСАРТАНА В СРАВНЕНИИ С ДРУГИМИ АНТАГОНИСТАМИ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II: ОБЗОР РАНДОМИЗИРОВАННЫХ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ
Olmesartan has a greater blood pressure-lowering effect than other angiotensin II type I receptor blockers, with clinically relevant differences in maximal efficacy and per-label recommended doses.
DOI